The proposal will be subject to a hearing until Oct. 8, after which a decision will be made by the Danish Medicines Agency. While GLP-1 drugs are significantly more expensive than other options, there is no general advantage in the treatment of patients suffering from type 2 diabetes.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment